{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05266417",
            "orgStudyIdInfo": {
                "id": "20-GTY-008-01"
            },
            "organization": {
                "fullName": "Gateway Institute for Brain Research",
                "class": "INDUSTRY"
            },
            "briefTitle": "Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Intranasal Insulin and Glutathione as an Add-On Therapy in Subjects With Parkinson's Disease (NOSE-PD)",
            "acronym": "NOSE-PD",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "intranasal-insulin-and-glutathione-as-an-add-on-therapy-in-parkinson-s-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-07",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-02-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-08-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-02-23",
            "studyFirstSubmitQcDate": "2022-02-23",
            "studyFirstPostDateStruct": {
                "date": "2022-03-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-04-21",
            "lastUpdatePostDateStruct": {
                "date": "2022-04-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gateway Institute for Brain Research",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo."
        },
        "conditionsModule": {
            "conditions": [
                "Parkinson Disease"
            ],
            "keywords": [
                "Insulin",
                "Glutathione",
                "Intranasal"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 56,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Active",
                    "type": "EXPERIMENTAL",
                    "description": "Insulin (Novolin R) and Glutathione (INS-GSH)",
                    "interventionNames": [
                        "Drug: INS-GSH"
                    ]
                },
                {
                    "label": "Control",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo",
                    "interventionNames": [
                        "Drug: Matched Placebos"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "INS-GSH",
                    "description": "Intranasal INS-GSH Twice Daily",
                    "armGroupLabels": [
                        "Active"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Matched Placebos",
                    "description": "Intranasal Matched Placebos Twice Daily",
                    "armGroupLabels": [
                        "Control"
                    ],
                    "otherNames": [
                        "Insulin Matched Placebo and Glutathione Matched Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Verbal Fluency",
                    "description": "F, A and S (FAS) words test",
                    "timeFrame": "24 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Verbal Fluency",
                    "description": "Change in verbal fluency as assessed by the FAS test",
                    "timeFrame": "28 Weeks"
                },
                {
                    "measure": "Motor Function",
                    "description": "Change in Timed Up and Go (TUG) test",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "Motor Function",
                    "description": "Change in the updated Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III total score",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "Motor Function",
                    "description": "Change in the updated MDS-UPDRS total score",
                    "timeFrame": "24 Weeks"
                },
                {
                    "measure": "Motor Function",
                    "description": "Change in the Clinical Global Impression (CGI) score",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Motor Function",
                    "description": "Change in Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD)",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Cognitive Function",
                    "description": "Change in each of the individual twelve (12) task standardized scores assessed using the Cambridge Brain Sciences (CBS) computerized neuropsychological battery",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Non-Motor Function",
                    "description": "Change in Hamilton Rating Scale for Depression total score",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Patient Reported Outcome",
                    "description": "Change in Parkinson's Disease Quality of Life Questionnaire (PDQ-39) assessment",
                    "timeFrame": "Week 24"
                },
                {
                    "measure": "Patient Reported Outcome",
                    "description": "Change in the Patient Global Impression (PGI) score",
                    "timeFrame": "Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Documented clinical diagnosis of idiopathic PD\n* Modified HY stage \\< 5\n* Able to administer study drug or have a caregiver throughout the duration of the study to help administer drug\n* Willing to continue diet, exercise and medications reported at baseline consistently throughout participation in the trial. Essential changes are permitted\n* If taking PD medications or any nutraceuticals, must be on a stable dose for at least 30 days prior to Screening Visit. Essential changes will be permitted.\n* If subject is taking chronic antidepressant or an anxiolytic, must be on a stable dose for at least 90 days prior to Screening. Essential changes will be permitted.\n\nKey Exclusion Criteria:\n\n* Clinical diagnosis of Type 1 or Type 2 Diabetes Mellitus\n* Glycated hemoglobin (HbA1c) level \u2265 6.5%\n* History of hypoglycemia and/or documented plasma glucose levels of \u2264 50 mg/dL with or without symptoms of hypoglycemia\n* Mini-Mental State Exam (MMSE) score of \u2264 24 at Screening\n* Positive COVID-19 test at Screening and/or within 30 days of Screening\n* Change in or escalation of dose of a chronic therapeutic agent that has the potential to impair cognitive functioning\n* Chronic inflammation of nasal cavity that may prevent absorption of study treatments\n* Insufficiently controlled respiratory disease (i.e., asthma, COPD).\n* History of any significant neurologic or psychiatric disease other than PD\n* Current diagnosis of epilepsy and had a history of seizures as an adult within 1 year of Screening, or unexplained recent loss of consciousness, or history of significant head trauma with loss of consciousness\n* History of non-lacunar ischemic and/or hemorrhagic stroke\n* Unstable or uncontrolled cardiac disease that could expose the subject to additional safety risks\n* Use of the following medications: Insulin or any other anti-hyperglycemic agent(s) except if used during isolated gestational diabetes, Supplementation with GSH or any medication shown to increase glutathione, and Beta Blockers",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "30 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Thomas Freeman",
                    "role": "CONTACT",
                    "phone": "(954) 636-2166",
                    "email": "tfreeman@gifbr.com"
                },
                {
                    "name": "Vanesa Aday",
                    "role": "CONTACT",
                    "phone": "(954) 636-2166",
                    "email": "vaday@gifbr.com"
                }
            ],
            "locations": [
                {
                    "facility": "Institute for Neuroimmune Medicine",
                    "status": "RECRUITING",
                    "city": "Davie",
                    "state": "Florida",
                    "zip": "33314",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Irina Rozenfeld, DN",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.06287,
                        "lon": -80.2331
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010300",
                    "term": "Parkinson Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020734",
                    "term": "Parkinsonian Disorders"
                },
                {
                    "id": "D000001480",
                    "term": "Basal Ganglia Diseases"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009069",
                    "term": "Movement Disorders"
                },
                {
                    "id": "D000080874",
                    "term": "Synucleinopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13213",
                    "name": "Parkinson Disease",
                    "asFound": "Parkinson's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22494",
                    "name": "Parkinsonian Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M25603",
                    "name": "Ganglion Cysts",
                    "relevance": "LOW"
                },
                {
                    "id": "M16358",
                    "name": "Synovial Cyst",
                    "relevance": "LOW"
                },
                {
                    "id": "M4774",
                    "name": "Basal Ganglia Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12029",
                    "name": "Movement Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2217",
                    "name": "Synucleinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007328",
                    "term": "Insulin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "asFound": "Day 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}